Top Markets
Coin of the day
Psyence Biomedical Ltd. Psyence Biomedical Ltd.

Psyence Biomedical Ltd.

PBM
Rankning i aktier #40930
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines... Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Aktiekurs
$3.20
Senast synkroniserad: 2026-07-31
Marknadsvärde
$60.86K
Förändring (1 dag)
-4.76%
Förändring (1 år)
-83.44%
Land
CA
Handel Psyence Biomedical Ltd. (PBM)

Kategori

EPS för Psyence Biomedical Ltd. (PBM)
EPS per 2026 TTM: 0
Enligt Psyence Biomedical Ltd.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Psyence Biomedical Ltd. från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter